Rewriting the immunology playbook aTyr Pharma (LIFE -1.59%) doesn't just develop drugs. The company is rewriting the rules of immunology. aTyr has discovered that transfer RNA synthetases -- proteins everyone thought just helped build other proteins -- actually moonlight as powerful immune system modulators. aTyr's lead drug, efzofitimod, just completed enrollment in its phase 3 EFZO-FIT trial for pulmonary sarcoidosis, with results expected in 2025's third quarter. Since EFZO-FIT is a single phase 3 trial, ...